1. Home
  2. ENOV vs IMTX Comparison

ENOV vs IMTX Comparison

Compare ENOV & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovis Corporation

ENOV

Enovis Corporation

HOLD

Current Price

$18.25

Market Cap

1.5B

Sector

Industrials

ML Signal

HOLD

IMTX

Immatics N.V.

HOLD

Current Price

$8.26

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENOV
IMTX
Founded
1995
N/A
Country
United States
Germany
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
ENOV
IMTX
Price
$18.25
$8.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
6
Target Price
★ $47.38
$19.00
AVG Volume (30 Days)
★ 1.9M
619.0K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$6.36
N/A
Revenue Next Year
$5.31
$25.91
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.30
$7.73
52 Week High
$34.28
$12.41

Technical Indicators

Market Signals
Indicator
ENOV
IMTX
Relative Strength Index (RSI) 36.42 40.04
Support Level $17.30 $8.36
Resistance Level $27.20 $10.51
Average True Range (ATR) 0.99 0.30
MACD 0.12 -0.03
Stochastic Oscillator 34.99 14.98

Price Performance

Historical Comparison
ENOV
IMTX

About ENOV Enovis Corporation

Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

About IMTX Immatics N.V.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Share on Social Networks: